Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

TNYA

Tenaya Therapeutics Inc

Mar 12 • 11:29AM ET

0.6302

Dollar change +0.0902
Percentage change 16.70	%

Healthcare • Biotechnology • USA • NASD

Peers: EDIT CRSP NTLA BEAM BMRN SRPT BLUE SGMO PSTX ABEO

| Held by: VTI VXF IWM VTWO IWN IWO IWC VTWV RSSL VTWG

Index	RUT	P/E	-	EPS (ttm)	-1.31	Insider Own	17.55%	Shs Outstand	154.22M	Perf Week	38.51%
Market Cap	97.19M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	263.82%	Shs Float	127.16M	Perf Month	-29.75%
Income	-111.13M	PEG	-	EPS next Q	-0.22	Inst Own	21.34%	Short Float	11.32%	Perf Quarter	-82.40%
Sales	0.00M	P/S	-	EPS this Y	33.16%	Inst Trans	-17.99%	Short Ratio	3.38	Perf Half Y	-73.85%
Book/sh	1.07	P/B	0.59	EPS next Y	6.03%	ROA	-75.64%	Short Interest	14.40M	Perf Year	-90.15%
Cash/sh	0.40	P/C	1.58	EPS next 5Y	-	ROE	-95.69%	52W Range	0.39 - 5.73	Perf YTD	-55.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.48%	ROI	-107.18%	52W High	-89.00%	Beta	3.01
Dividend TTM	-	Quick Ratio	4.22	Sales past 5Y	0.00%	Gross Margin	-	52W Low	59.91%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	4.22	EPS Y/Y TTM	23.55%	Oper. Margin	-	RSI (14)	35.76	Volatility	16.26% 15.08%
Employees	97	Debt/Eq	0.15	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	11.86
Option/Short	Yes / Yes	LT Debt/Eq	0.12	EPS Q/Q	37.02%	Payout	-	Rel Volume	6.88	Prev Close	0.54
Sales Surprise	-	EPS Surprise	9.91%	Sales Q/Q	-	Earnings	Mar 10 AMC	Avg Volume	4.26M	Price	0.63
SMA20	-26.37%	SMA50	-42.64%	SMA200	-72.88%	Trades		Volume	9,949,439	Change	16.70%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-24	Initiated	William Blair	Outperform
Nov-30-23	Initiated	Leerink Partners	Outperform	$7
Jun-15-22	Initiated	H.C. Wainwright	Buy	$25

Mar-10-25 04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +11.14% +6.78%
Mar-03-25 11:19PM	Tenaya Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -6.25% -53.53%
04:10PM	Tenaya Therapeutics Announces Proposed Public Offering (GlobeNewswire)
08:00AM	Tenaya Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 08:30AM	Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine (GlobeNewswire)
09:16AM	Loading…
Jan-13-25 09:16AM	Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Dec-17-24 07:00AM	Tenaya Therapeutics Reports Promising Early Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire) -51.04%
Dec-16-24 04:30PM	Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 (GlobeNewswire)
Nov-25-24 08:30AM	Tenaya Therapeutics Doses First Patient in RIDGE-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) +24.37%
Nov-19-24 08:00AM	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +10.19%
Nov-06-24 04:05PM	Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +12.11%
Nov-03-24 06:11AM	Morgan Stanley Predicts Up to 670% Jump for These 2 Strong Buy Stocks (TipRanks)
Oct-17-24 04:30PM	Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM (GlobeNewswire) +22.86% -5.12%
Sep-03-24 08:30AM	Tenaya Therapeutics to Participate in Upcoming Investment Conferences (GlobeNewswire) -5.60%
Aug-08-24 04:05PM	Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.10%
05:00PM	Loading…
Jun-27-24 05:00PM	Tenaya Therapeutics Announces Research Leadership Updates (GlobeNewswire) +8.09% +5.44%
Jun-18-24 04:30PM	Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit (GlobeNewswire)
May-16-24 12:21PM	Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating (MT Newswires)
May-15-24 07:00AM	Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170 (BioPharma Dive)
May-14-24 10:54PM	TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-02-24 05:00PM	Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Mar-26-24 07:19AM	20 Countries with the Highest Heart Disease Deaths Per Capita (Insider Monkey)
Mar-20-24 05:32AM	Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results (GuruFocus.com) +8.17%
Mar-18-24 10:53PM	TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -6.02%
04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-27-24 04:30PM	Tenaya Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
09:55AM	Loading…
Feb-26-24 09:55AM	Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross? (Zacks) +9.00%
08:30AM	Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications (GlobeNewswire)
Feb-09-24 09:55AM	Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet (Zacks) +10.72%
Feb-08-24 08:00AM	Tenaya Therapeutics Announces Pricing of Underwritten Offering (GlobeNewswire) +16.06%
Jan-26-24 12:00PM	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-03-24 08:30AM	Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.28%
Nov-21-23 04:30PM	Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-08-23 04:05PM	Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-26-23 08:30AM	Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) -5.67%
Oct-09-23 08:30AM	Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting (GlobeNewswire)
Oct-05-23 08:30AM	Tenaya Therapeutics Doses First Patient in the MyPeak-1 Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire)
Oct-02-23 05:30PM	Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration (GlobeNewswire) -5.24%
Sep-21-23 04:05PM	Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences (GlobeNewswire) +6.06%
Aug-31-23 04:05PM	Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference (GlobeNewswire) -5.38%
Aug-09-23 04:05PM	Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Aug-02-23 04:05PM	Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference (GlobeNewswire)
May-30-23 09:06AM	With 35% stake, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) seems to have captured institutional investors' interest (Simply Wall St.)
May-15-23 09:55AM	Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade (Zacks)
May-11-23 08:50AM	Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) +7.65%
May-10-23 04:19PM	Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-03-23 08:00AM	Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting (GlobeNewswire) +12.36%
07:09AM	We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-02-23 07:50AM	Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201 (GlobeNewswire) -11.30%
Apr-25-23 06:35AM	The 7 Best Biotech Stocks for Personalized Medicine Investors (InvestorPlace) -5.77%
Apr-23-23 04:02PM	3 Penny Stocks to Buy for 100% Returns (InvestorPlace)
Apr-21-23 04:05PM	Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire) +22.79%
Apr-20-23 02:46PM	Why This Nasdaq Stock Caught Fire This Week (Motley Fool) +26.08%
Apr-19-23 11:36AM	These 2 Strong Buy Penny Stocks Could Rally to $40 (or More), Says Piper Sandler (TipRanks) +17.16%
Mar-08-23 04:01PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -6.96% -12.57%
Feb-07-23 05:17PM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-26-23 12:00PM	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know (Zacks)
Jan-09-23 07:00AM	Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones (GlobeNewswire)
Dec-21-22 06:12AM	Insiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% drop (Simply Wall St.)
Dec-07-22 04:30PM	Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors (GlobeNewswire)
Dec-02-22 06:36PM	IRobot and Acrivon Stock See Action From Activist Investors (Barrons.com)
Nov-28-22 08:30AM	Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) +7.11%
Nov-24-22 05:54AM	Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely (Simply Wall St.)
Nov-23-22 09:00AM	Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-21-22 05:45PM	Tenaya Therapeutics Announces Closing of Public Offering (GlobeNewswire) +9.44%
Nov-17-22 12:39AM	Tenaya Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -21.63%
Nov-16-22 04:01PM	Tenaya Therapeutics Announces Proposed Public Offering (GlobeNewswire) +8.87%
Nov-10-22 04:05PM	Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.81% +30.88%
Nov-04-22 08:00AM	Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022 (GlobeNewswire) -17.87%
Oct-14-22 06:12AM	Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) 17% loss last week hit both individual investors who own 40% as well as institutions (Simply Wall St.)
Oct-04-22 08:30AM	Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress (GlobeNewswire)
Sep-29-22 08:00AM	Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions (GlobeNewswire) -10.42%
07:45AM	Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences (GlobeNewswire)
Sep-26-22 09:21AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Sep-15-22 09:39AM	Harvard Universitys Latest Portfolio: 10 Best Biotech Stock Picks (Insider Monkey)
Sep-06-22 04:05PM	Tenaya Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) -7.24% +8.51%
08:00AM	Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction (GlobeNewswire)
Aug-16-22 09:55AM	Does Tenaya Therapeutics, Inc. (TNYA) Have the Potential to Rally 368% as Wall Street Analysts Expect? (Zacks) -7.50%
Aug-10-22 04:01PM	Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-06-22 02:00PM	Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure (GlobeNewswire)
Jun-16-22 08:00AM	Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics (Business Wire)
May-20-22 08:30AM	Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference (Business Wire) +18.33%
May-11-22 04:09PM	Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire) -12.00% +7.12%
May-07-22 09:38AM	We're Not Very Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate (Simply Wall St.)
May-03-22 08:00AM	Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting (Business Wire)
Apr-28-22 08:00AM	Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022 (Business Wire) +5.34%
Mar-24-22 08:30AM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +12.51%
Mar-23-22 04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates (Business Wire) -5.76%
Feb-08-22 12:01PM	Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA) (Zacks)
Feb-04-22 01:03PM	What Is The Ownership Structure Like For Tenaya Therapeutics, Inc. (NASDAQ:TNYA)? (Simply Wall St.) +7.56%
Jan-31-22 08:00AM	Tenaya Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +14.40%
Jan-10-22 08:00AM	Tenaya Therapeutics Provides 2022 Business Updates (Business Wire) -6.86%
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... (GuruFocus.com)
Dec-22-21 04:05PM	Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture (Business Wire) +8.98%
Dec-17-21 10:06AM	Harvard University Stock Portfolio: 8 Latest Stock Picks (Insider Monkey)
Nov-22-21 08:00AM	Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors (Business Wire) -8.27%

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Higa Tomohiro	SVP, Finance	Mar 10 '25	Sale	0.54	2,482	1,336	99,690	Mar 10 09:44 PM
Tingley Whittemore	Chief Medical Officer	Mar 10 '25	Sale	0.54	7,398	3,983	174,793	Mar 10 09:43 PM
Ali Faraz	Chief Executive Officer	Mar 10 '25	Sale	0.54	9,741	5,245	320,514	Mar 10 09:42 PM
Whittemore Tingley	Officer	Mar 10 '25	Proposed Sale	0.54	7,398	3,983		Mar 10 09:41 PM
Faraz Ali	Officer	Mar 10 '25	Proposed Sale	0.54	9,741	5,245		Mar 10 09:40 PM
COLUMN GROUP III GP, LP	10% Owner	Mar 05 '25	Buy	0.70	35,714,284	24,999,999	49,313,559	Mar 07 07:14 PM
GOEDDEL DAVID V	Director	Mar 05 '25	Buy	0.70	35,714,284	24,999,999	49,313,559	Mar 07 07:14 PM
Saito Chihiro	SVP, Accounting and Fin. Ops.	Nov 18 '24	Sale	2.12	2,258	4,787	60,983	Nov 18 08:48 PM
Saito Chihiro	SVP, Accounting and Fin. Ops.	Aug 16 '24	Sale	2.89	2,363	6,840	63,241	Aug 19 08:30 PM
Tingley Whittemore	Chief Medical Officer	Aug 16 '24	Sale	2.89	7,428	21,500	107,106	Aug 16 08:26 PM
Ali Faraz	Chief Executive Officer	Aug 16 '24	Sale	2.89	9,748	28,216	188,331	Aug 16 08:25 PM
Whittemore Tingley	Officer	Aug 16 '24	Proposed Sale	2.89	7,428	21,467		Aug 16 08:24 PM
Faraz Ali	Officer	Aug 16 '24	Proposed Sale	2.89	9,748	28,172		Aug 16 08:23 PM

Open in Screener

SRZN

Surrozen Inc

Mar 12 • 11:21AM ET

11.55

Dollar change +0.20
Percentage change 1.76	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY VRTX BIIB SRPT CRSP NTLA IONS EDIT BLUE ARWR

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-16.99	Insider Own	30.83%	Shs Outstand	3.25M	Perf Week	-1.11%
Market Cap	37.54M	Forward P/E	-	EPS next Y	-10.71	Insider Trans	-0.20%	Shs Float	2.25M	Perf Month	15.50%
Income	-44.44M	PEG	-	EPS next Q	-2.54	Inst Own	60.63%	Short Float	6.49%	Perf Quarter	13.91%
Sales	10.00M	P/S	3.75	EPS this Y	29.96%	Inst Trans	49.83%	Short Ratio	4.38	Perf Half Y	35.88%
Book/sh	1.74	P/B	6.62	EPS next Y	28.31%	ROA	-87.16%	Short Interest	0.15M	Perf Year	-13.48%
Cash/sh	9.54	P/C	1.21	EPS next 5Y	18.19%	ROE	-173.59%	52W Range	6.00 - 18.17	Perf YTD	-19.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-784.15%	52W High	-36.43%	Beta	0.70
Dividend TTM	-	Quick Ratio	7.40	Sales past 5Y	-33.33%	Gross Margin	84.29%	52W Low	92.50%	ATR (14)	0.92
Dividend Ex-Date	-	Current Ratio	7.40	EPS Y/Y TTM	2.12%	Oper. Margin	-266.31%	RSI (14)	51.22	Volatility	6.43% 7.93%
Employees	42	Debt/Eq	0.27	Sales Y/Y TTM	-20.00%	Profit Margin	-444.38%	Recom	1.00	Target Price	38.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	91.35%	Payout	-	Rel Volume	0.15	Prev Close	11.35
Sales Surprise	-	EPS Surprise	82.15%	Sales Q/Q	-	Earnings	Nov 06 BMO	Avg Volume	33.35K	Price	11.55
SMA20	1.30%	SMA50	-2.02%	SMA200	12.10%	Trades		Volume	1,693	Change	1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-25	Initiated	H.C. Wainwright	Buy	$32
Jan-03-25	Upgrade	Guggenheim	Neutral → Buy	$45
Oct-11-21	Initiated	BofA Securities	Buy	$11
Sep-15-21	Initiated	Guggenheim	Buy	$20
Sep-07-21	Initiated	Stifel	Buy	$19

Nov-06-24 04:30PM	Surrozen to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) -5.12%
09:00AM	Surrozen Provides Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-04-24 08:30AM	Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF- Antibodies for Idiopathic Pulmonary Fibrosis (GlobeNewswire) -10.20%
Sep-24-24 08:30AM	Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration (GlobeNewswire) +8.70%
Aug-12-24 04:05PM	Surrozen Provides Second Quarter 2024 Financial Results and Business Update (GlobeNewswire) -10.14%
08:30AM	Loading…
Jun-12-24 08:30AM	Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling (GlobeNewswire)
Jun-10-24 08:30AM	Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan (GlobeNewswire)
Jun-04-24 08:30AM	Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis (GlobeNewswire)
May-09-24 08:30AM	Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
May-08-24 11:55PM	SRZN Stock Earnings: Surrozen Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Surrozen Provides First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-03-24 08:40AM	Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis (GlobeNewswire) +13.41%
Apr-01-24 08:30AM	Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -35.71%
08:30AM	Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 (GlobeNewswire)
09:58AM	Loading…
Jan-18-24 09:58AM	Surrozen stops IBD program due to dose concerns and competition (FierceBiotech.com) -5.53%
08:30AM	Surrozen Provides Corporate Update on Clinical Programs (GlobeNewswire)
Dec-14-23 05:52AM	SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023 (InvestorPlace) +9.33%
05:51AM	SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023 (InvestorPlace)
Nov-08-23 04:05PM	Surrozen Provides Third Quarter 2023 Financial Results (GlobeNewswire) -21.17%
Aug-09-23 04:05PM	Surrozen Provides Second Quarter 2023 Financial Results (GlobeNewswire) +5.52% -32.19%
Jun-05-23 08:30AM	Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke (GlobeNewswire)
May-10-23 04:05PM	Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates (GlobeNewswire) -9.43%
Apr-05-23 08:30AM	Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt (GlobeNewswire)
Mar-28-23 04:59AM	Surrozen, Inc. (NASDAQ:SRZN) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.52%
Mar-22-23 04:01PM	Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress (GlobeNewswire) -22.52%
Mar-20-23 04:30PM	Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023 (GlobeNewswire) +21.18%
Jan-04-23 04:41PM	Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-14-22 04:30PM	Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -30.17%
Oct-10-22 08:00AM	Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week (GlobeNewswire)
08:00AM	Loading…
Oct-06-22 08:00AM	Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases (GlobeNewswire)
Sep-26-22 08:00AM	Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy (GlobeNewswire)
Aug-11-22 08:00AM	Surrozen Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-27-22 10:34AM	What Is The Ownership Structure Like For Surrozen, Inc. (NASDAQ:SRZN)? (Simply Wall St.)
Jun-13-22 08:00AM	Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis (GlobeNewswire)
May-24-22 08:00AM	Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) (GlobeNewswire) -5.75%
May-18-22 08:00AM	Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis (GlobeNewswire) +7.29%
May-16-22 08:00AM	Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD) (GlobeNewswire)
May-11-22 08:00AM	Surrozen Reports First Quarter 2022 Financial Results (GlobeNewswire) -8.74%
May-05-22 08:00AM	Surrozen to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire) -12.88%
May-02-22 08:00AM	Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
Mar-24-22 08:00AM	Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -6.03%
Jan-20-22 09:00AM	Heartland Express, Inc. Reports Fourth Quarter and Annual Financial Results which includes All-Time Record High Annual Earnings Per Share (GlobeNewswire) -7.62%
Jan-10-22 08:00AM	Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline (GlobeNewswire)
Jan-05-22 08:00AM	Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-21 04:00PM	Surrozen Reports Third Quarter 2021 Financial Results (GlobeNewswire)
08:00AM	Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
08:00AM	Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (GlobeNewswire)
Nov-11-21 10:51AM	How Many Surrozen, Inc. (NASDAQ:SRZN) Shares Do Institutions Own? (Simply Wall St.) +19.50%
Nov-05-21 08:00AM	Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference (GlobeNewswire)
Oct-05-21 04:30PM	Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week (GlobeNewswire) -5.75%
Sep-23-21 08:30AM	Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources (GlobeNewswire) -9.07%
Aug-11-21 05:30PM	Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration (GlobeNewswire)

Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Li Yang	Exec. Vice President, Research	Jan 03 '25	Sale	17.37	843	14,643	13,345	Jan 06 09:13 PM
Williams Charles O	CFO and COO	Jan 03 '25	Sale	17.37	1,181	20,514	8,982	Jan 06 08:07 PM
Kutzkey Tim	Director	Apr 04 '24	Buy	15.50	193,548	2,999,994	332,885	Apr 08 04:24 PM
COLUMN GROUP III GP, LP	10% Owner	Apr 04 '24	Buy	15.50	193,548	2,999,994	332,885	Apr 08 04:23 PM

TNYA

Tenaya Therapeutics Inc

SRZN

Surrozen Inc

Upgrade your FINVIZ experience